NEW YORK, Aug. 23, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024. DexCom describes itself as an "international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management." A class action has already been filed. If you wish to serve as lead plaintiff, you must move ...

SAN DIEGO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom and certain of DexCom’s top executives with ...

NEW YORK, Aug. 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ: DXCM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether DexCom and certain of its officers and/or d ...

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”). For more information, submit a form at DexCom, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, o ...

ATLANTA, Aug. 22, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM). The lawsuit alleges that Defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth while also minimizing risk from seasonality and macroeconomic fluctuations. Such statements are alleged to have caused Plaintiff and other shareholders to purchase DexCom’ ...

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of California on behalf of all persons or entities who purchased or otherwise acquired DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the federal secu ...

LOS ANGELES, Aug. 22, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between January 8, 2024 and July 25, 2024, inclusive (the "Class Period"), are encou ...

NEW YORK, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and ...

文章核心观点 - 公司股价自2021年11月高点下跌55%,低于同期竞争对手Insulet下跌39%,主要由于销售增长放缓,部分原因是GLP-1药物的益处提高帮助患者控制糖尿病和减重 [2] - 公司股价表现波动较大,2021年上涨45%,2022年下跌16%,2023年上涨10%,而标普500指数同期分别上涨27%、下跌19%和上涨24%,公司股价在2023年表现不佳 [3] - 从估值角度来看,公司股价处于低估状态,分析师平均目标价为99美元,较当前水平有35%的上涨空间 [4] 公司基本面分析 - 公司收入在过去两年翻倍至39亿美元,新客户增加是收入增长的主要驱动因素,公司是为数不多获得监管批准的可穿戴式持续血糖监测设备供应商之一 [8] - 公司营业利润率从2020年的15.5%提升至17.3% [8] - 公司债务从2020年的18亿美元增加至26亿美元,但现金余额也从27亿美元增加至31亿美元,加上过去12个月获得的9亿美元经营活动现金流,公司有足够的现金缓冲应对当前的通胀冲击 [10] 行业发展趋势 - 随着美联储努力遏制通胀,我们认为公司股价有望在消除对潜在衰退的担忧后获得上涨 [11] - 但肥胖药物的更广泛应用及其对公司业务的影响仍是一个关键风险因素 [11] - 要回到通胀冲击前的水平,公司股价还需要上涨120%以上,这在短期内可能难以实现 [11]

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com 844-916-0895 DexCom, Inc. (DXCM) Securities Class Action: Dex ...